Protalix BioTherapeutics, Inc. (PLX) Investor Relations Documents

Protalix BioTherapeutics, Inc. (PLX) investor relations documents from the company's IR site: 9 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-12	Press release	Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
2026-08-05	Press release	Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
2026-05-13	Press release	Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
2026-05-06	Press release	Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
2026-03-18	Press release	Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
2026-03-11	Press release	Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
2026-03-09	Press release	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regi
2026-01-30	Press release	Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen
2026-01-05	Press release	Protalix BioTherapeutics Letter to Stockholders

PLX overview · PLX earnings · PLX financials · PLX KPIs · PLX ownership · PLX peers · PLX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.